COMMUNIQUÉS West-GlobeNewswire

AccuStem Sciences, Inc. Announces Chairman Purchase of Shares
03/01/2025
LONDON and PHOENIX, Jan. 03, 2025 (GLOBE NEWSWIRE) -- AccuStem Sciences, Inc. (OTCQB: ACUT), a clinical stage diagnostics company dedicated to improving outcomes for patients with cancer, announced that its Chairman of [...]
Eton Pharmaceuticals Advances Its Commitment to Rare Disease with the Acquisition of Galzin®
03/01/2025
Adds an additional commercial and strategic rare disease product to Eton’s portfolio Galzin is FDA-approved for the treatment of the ultra-rare metabolic condition of Wilson Disease DEER PARK, Ill., Jan. 03, 2025 (GLOBE [...]
SpringWorks Therapeutics to Present at the 43rd Annual J.P. Morgan Healthcare Conference
03/01/2025
STAMFORD, Conn., Jan. 03, 2025 (GLOBE NEWSWIRE) -- SpringWorks Therapeutics, Inc. (Nasdaq: SWTX), a commercial-stage biopharmaceutical company focused on severe rare diseases and cancer, today announced that Saqib Islam [...]
Trading by management and close relations of management
03/01/2025
In accordance with article 19 in Regulation (EU) No 596/2014 of 16 April 2014 on market abuse (the Market Abuse Regulation) and commission delegated regulation (EU) 1052/2016 of 8 March 2016, Novozymes A/S, part of [...]
ACELYRIN, INC. to Host Virtual Investor Event to Share new Phase 2 Data and Phase 3 Program Design for Subcutaneous Lonigutamab
03/01/2025
LOS ANGELES, Jan. 02, 2025 (GLOBE NEWSWIRE) -- ACELYRIN, INC. (Nasdaq: SLRN), a late-stage clinical biopharma company focused on accelerating the development and delivery of transformative medicines in immunology, today [...]
LENSAR Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
03/01/2025
ORLANDO, Fla., Jan. 02, 2025 (GLOBE NEWSWIRE) -- LENSAR, Inc. (Nasdaq: LNSR) (“LENSAR” or the “Company”) today announced that a majority of the independent members of LENSAR’s board of directors granted three newly- [...]
Tilray Brands Moves Earnings Date to January 10, 2025, in Observance of the National Day of Mourning
02/01/2025
Due to the closure of the Securities and Exchange Commission and U.S. stock markets on January 9, in honor of the late former President Jimmy Carter, Tilray has moved its earnings announcement to January 10 NEW YORK and [...]
Zentalis Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
02/01/2025
SAN DIEGO, Jan. 02, 2025 (GLOBE NEWSWIRE) -- Zentalis® Pharmaceuticals, Inc. (Nasdaq: ZNTL), a clinical-stage biopharmaceutical company discovering and developing clinically differentiated small molecule therapeutics [...]
Pennant Completes Acquisition of Signature Healthcare at Home Assets
02/01/2025
EAGLE, Idaho, Jan. 02, 2025 (GLOBE NEWSWIRE) -- The Pennant Group, Inc. (NASDAQ: PNTG), the parent company of the Pennant group of affiliated home health, hospice, and senior living companies, today announced that it [...]
The Pennant Group Appoints Brent Guerisoli as Chairman and Scott Lamb as Lead Independent Director
02/01/2025
EAGLE, Idaho, Jan. 02, 2025 (GLOBE NEWSWIRE) -- The Pennant Group, Inc. (NASDAQ: PNTG), the parent company of the Pennant group of affiliated home health, hospice, and senior living companies, today announced the [...]
Certara to Participate in the 43rd Annual J.P. Morgan Healthcare Conference
02/01/2025
RADNOR, Pa., Jan. 02, 2025 (GLOBE NEWSWIRE) -- Certara, Inc. (Nasdaq: CERT), a global leader in model-informed drug development, today announced that Company management will participate in the 43 rd Annual J.P. Morgan [...]
Treace to Present at 43rd Annual J.P. Morgan Healthcare Conference
02/01/2025
PONTE VEDRA, Fla., Jan. 02, 2025 (GLOBE NEWSWIRE) -- Treace Medical Concepts, Inc. (“Treace” or the “Company”) (NasdaqGS: TMCI), a medical technology company driving a fundamental shift in the surgical treatment of [...]
Lifecore Biomedical Reports Second Quarter Fiscal 2025 Financial Results and Provides Corporate Update
02/01/2025
-- Recorded Revenues of $32.6 Million for Q2 Fiscal 2025 -- -- Signed Multiple Development Agreements with New Customers -- -- Strengthened Balance Sheet with Financing Raising Approximately $24.3 Million, and Favorable [...]
RxSight, Inc. to Present at the J.P. Morgan Healthcare Conference
02/01/2025
ALISO VIEJO, Calif., Jan. 02, 2025 (GLOBE NEWSWIRE) -- (NASDAQ: RXST) – RxSight, Inc., an ophthalmic medical device company dedicated to providing high-quality customized vision to patients following cataract surgery, [...]
Terns Pharmaceuticals Reports Inducement Grant to New Employee Under Nasdaq Listing Rule 5635(C)(4)
02/01/2025
FOSTER CITY, Calif., Jan. 02, 2025 (GLOBE NEWSWIRE) -- Terns Pharmaceuticals, Inc. (“Terns” or the “Company”) (Nasdaq: TERN), a clinical-stage biopharmaceutical company developing a portfolio of small-molecule product [...]
Adaptive Biotechnologies to Present at the 43rd Annual J.P. Morgan Healthcare Conference
02/01/2025
SEATTLE, Jan. 02, 2025 (GLOBE NEWSWIRE) -- Adaptive Biotechnologies Corporation (Nasdaq: ADPT), a commercial stage biotechnology company that aims to translate the genetics of the adaptive immune system into clinical [...]
PacBio to Present at 43rd Annual J.P. Morgan Healthcare Conference
02/01/2025
MENLO PARK, Calif., Jan. 02, 2025 (GLOBE NEWSWIRE) -- PacBio (NASDAQ: PACB), a leading developer of high-quality, highly accurate sequencing solutions, announced today that management will be presenting at the 43rd [...]
Seer to Present at the J.P. Morgan 43rd Annual Healthcare Conference
02/01/2025
REDWOOD CITY, Calif., Jan. 02, 2025 (GLOBE NEWSWIRE) -- Seer, Inc. (Nasdaq: SEER), a leading life sciences company commercializing a disruptive new platform for proteomics, today announced that the company will be [...]
Pacira BioSciences to Present at the 43rd Annual J.P. Morgan Healthcare Conference
02/01/2025
PARSIPPANY, N.J., Jan. 02, 2025 (GLOBE NEWSWIRE) -- Pacira BioSciences, Inc. (NASDAQ: PCRX) today announced that it will present at the 43 r d Annual J.P. Morgan Healthcare Conference at 10:30 AM PT (1:30 PM EST) on [...]

Pages